


Supplementary figure 3



Supplementary figure 3: Effect of company size on total procedure time. a) Total procedure time, CHMP assessment time, total clock stop time and first clock stop time of medium-sized and large companies compared with small companies. **b)** Percentage of marketing authorization applications (MAAs) that were granted a positive CHMP opinion or a negative CHMP opinion for medium-sized and large companies compared with small companies. **c)** Total procedure time of MAAs of small companies with a positive CHMP opinion compared with MAAs of small

companies with a negative CHMP opinion. **d)** Number of scientific advice (SA) meetings companies had during the development of the medicinal product, shown as percentage of total MAAs of medium-sized and large companies or small companies. **e)** Number of scientific advice (SA) meetings small companies had during the development of the medicinal product, shown as percentage of total MAAs of small companies with a positive CHMP opinion or negative CHMP opinion. **a-e)** Products that were granted accelerated assessment were excluded. **a,c)** Values are expressed as mean $\pm$ SD. CHMP: Committee for Medicinal Products for Human Use.

Article title: A decade of marketing authorization applications of anticancer drugs in the European Union: an analysis of procedural timelines

Journal name: Therapeutic Innovation & Regulatory Science

Author names: Marjolein Garsen¹, Maaike Steenhof¹, Alex Zwiers¹

Affiliation: ¹Zwiers Regulatory Consultancy, Oss, the Netherlands

Email address of the corresponding author: Marjolein.Garsen@az-regulatory.com